CDK2 and non-small cell lung carcinoma: Moreover, immunoblotting revealed that BA or trametinib alone reduced the levels of CDK2, CDK4, and cyclin D1, and the combination of both induced a synergistic decrease in the levels of those proteins in NSCLC cells (Figure 6B).